Effect of a Spirolactone on Plasma and Urinary Aldosterone in Primary Aldosteronism

Authors:
  • HVH. Vetter
    H. Vetter
  • MAM. Appenheimer
    M. Appenheimer
  • RLR. Lucas
    R. Lucas
  • HWH. Weiand
    H. Weiand
  • MHM.L. Herschbach
    M.L. Herschbach
  • KGK. GlÄNzer
    K. GlÄNzer
  • FWF. Witassek
    F. Witassek
  • FKF. KrÜCk
    F. KrÜCk

Abstract
In primary aldosteronism due to an adrenal adenoma (n = 2), treatment with a spirolactone (160 mg Canrenone/day for 7 days) decreased plasma aldosterone and urinary aldosterone-18-glucuronide. However, in the presence of a normalization in urinary aldosterone-18-glucuronide plasma aldosterone remained elevated above normal. Continued therapy with higher doses (320 mg/day for 7 days and 480 mg/day for 28 days) did not significantly alter plasma aldosterone, while urinary aldosterone-18-glucuronide returned to values comparable to those obtained before therapy. Cessation of the drug resulted in a marked increase in plasma aldosterone and urinary aldosterone-18-glucuronide. The results indicate that in primary aldosteronism due to an adrenal adenoma, the spirolactone (Canrenone) inhibits aldosterone biosynthesis and seems to influence aldosterone degradation.